Neuland Laboratories reported FY26 total income of Rs2053.1 crore and EBITDA of Rs603.4 crore.
Q4 FY26 showed exceptional growth with 134.9% YoY income increase and 448.6% YoY EBITDA surge.
Management highlighted strong business visibility and ongoing investments in peptide manufacturing and R&D.
Company announced earnings call for May 12, 2026, to discuss FY26 performance and outlook.